Cargando…
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
BACKGROUND: Intravitreal ranibizumab prevents vision loss and improves visual acuity in patients with neovascular age-related macular degeneration, but it is expensive, and efficacy beyond 2 years is uncertain. METHODS: We assessed the cost-effectiveness of ranibizumab compared with no ranibizumab o...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2443361/ https://www.ncbi.nlm.nih.gov/pubmed/18573218 http://dx.doi.org/10.1186/1478-7547-6-12 |